Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Share-based Compensation: 2015-2024

Historic Share-based Compensation for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Dec 2024 value amounting to $39.7 million.

  • Rhythm Pharmaceuticals' Share-based Compensation rose 70.98% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.1 million, marking a year-over-year increase of 53.72%. This contributed to the annual value of $39.7 million for FY2024, which is 21.90% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Share-based Compensation of $39.7 million as of FY2024, which was up 21.90% from $32.6 million recorded in FY2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Share-based Compensation peaked at $39.7 million during FY2024, and registered a low of $17.5 million during FY2020.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Share-based Compensation value was $32.6 million (recorded in 2023), while the average stood at $30.7 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Share-based Compensation declined by 4.68% in 2022 and then skyrocketed by 64.15% in 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Share-based Compensation (Yearly) stood at $17.5 million in 2020, then climbed by 19.19% to $20.8 million in 2021, then dropped by 4.68% to $19.8 million in 2022, then soared by 64.15% to $32.6 million in 2023, then increased by 21.90% to $39.7 million in 2024.